▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.View More ⏩Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH
Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and its evolving terminology, diagnostic challenges, and association with cardio-metabolic syndrome. Learn about its progressive nature, the gold standard for diagnosis, and the emerging role of biomarkers. A must-read for healthcare professionals aiming for early diagnosis and effective management.View More ⏩Clinical Chemistry in NAFLD Part 1 – Interest and Why?
Explore ADA’s 2023 updates on diabetes care, focusing on non-alcoholic fatty liver disease (NAFLD) and cirrhosis prevention. Learn from Dr. Kenneth Cusi on risk stratification, diagnostic tools like FIB-4, and latest management recommendations.View More ⏩Updates in ADA’s 2023 Standard of Care in Diabetes
Unveiling the high prevalence of NAFLD and advanced fibrosis in type 2 diabetes patients - a deep-dive into two groundbreaking studies from the US and France. Explore the findings and their implications for future diabetes care.View More ⏩Key Messages from 2 Recent Studies on NAFLD Severity in People with Type 2 Diabetes
On International NASH Day 2023, join Michael Betel of the Fatty Liver Alliance as he addresses NAFLD and NASH, their prevalence and impact. Discover solutions including medical education, patient awareness, and advocacy. Learn about the Alliance's future goals.View More ⏩Building a Better Future For Patients with NAFLD and NASH
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between non-alcoholic fatty liver disease (NAFLD) and heart failure. Uncover the paramount importance of comprehending the intersection between these two conditions in our pursuit of adequate healthcare solutions.View More ⏩Link Between NAFLD and Heart Failure – A Cardiology Perspective
Discover the importance of a multistakeholder approach in NAFLD care, addressing the challenges of comorbidities, patient identification, and innovative strategies to improve treatment outcomes and healthcare coordination.View More ⏩Multistakeholder Approach to Innovations in NAFLD Care
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic steatohepatitis (NASH) with insights from Dr Giada Sebastiani, associate professor of medicine at McGill University Health Center in Canada.View More ⏩The Odyssey for an Optimal NASH Biomarker: Challenges and Opportunities in 2023
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and can be evident in the early stages which is caused by intrahepatic vascular alterations. Further, he explores the different types of drugs that will help change the course of the disease.View More ⏩NAFLD Pathophysiologic Role of Intrahepatic Vasculature
Dr. Jörn Schattenberg (Germany) analyses the latest on the assessment in cirrhosis along with his own case study.View More ⏩Non-Invasive Assessment of cACLD and Portal Hypertension
Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH as NASH is the progressive form of the disease and drives fibrosis progression. This means the question arises on whether anti-fibrotic drugs are better than anti-NASH drugs and vice versa which Dr. Vlad Ratziu explores in this video.View More ⏩Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular disease, but this does not prove bidirectional causality. Vascular mechanisms contribute to NASH pathogenesis and drugs used in CVD management show some benefit on NAFLD.View More ⏩Burden of Liver-Related Comorbidities in Cardiovascular Disease